The Most Powerful Anti-Aging Drug (Vaccines?)

#1

In people. More powerful anti-aging than rapamycin shown (rather than speculated) in humans - vaccines: 19%.

The most powerful anti-aging drug: vaccines?! (via Viva Longevity!)

6 Likes
Beyond the Rash: The Shingles Vaccination as a Multi-System Longevity Intervention
#2

I. Executive Summary

The core thesis of the presentation—that routine vaccinations (Influenza, Herpes Zoster, Tdap, Pneumococcal) provide significant “off-target” protection against Alzheimer’s disease (AD), cardiovascular events, and biological aging—is increasingly supported by large-scale observational and quasi-experimental data. The primary mechanism involves “trained immunity” (reprogramming of innate immune cells) and the mitigation of “inflammaging” (chronic systemic inflammation).

Most notably, recent data from 2026 indicates that the high-dose influenza vaccine reduces AD risk by approximately 55% in adults over 65, significantly outperforming the standard-dose vaccine (40% reduction). Furthermore, the Herpes Zoster (Shingles) vaccine has demonstrated a 46% reduction in major cardiac events and a 66% reduction in all-cause mortality within the first year of administration in high-risk populations. While these numbers are statistically staggering, they must be interpreted through the lens of Healthy User Bias: individuals who adhere to vaccination schedules often exhibit other health-seeking behaviors (e.g., better diet, higher exercise frequency, superior socioeconomic status).

However, the “gold standard” evidence in this field has evolved beyond simple propensity score matching. New Regression Discontinuity studies (e.g., the 2026 Stanford study in Wales/Canada) utilize birth-date cutoffs for vaccine eligibility to create a “natural experiment” that effectively isolates the vaccine’s effect from lifestyle variables. These studies confirm a ~20% reduction in dementia risk directly attributable to the shingles vaccine.

Biologically, these interventions appear to lower systemic inflammatory markers (CRP, IL-6) and slow epigenetic aging. For the aging population, vaccines are no longer merely tools for preventing acute infection; they are emerging as a pragmatic, low-cost strategy for extending healthspan and reducing the burden of age-related chronic diseases.

II. Insight Bullets

  • Dose-Response Relationship: High-dose flu vaccines provide a ~15% greater reduction in Alzheimer’s risk compared to standard doses Schultz et al., 2026.
  • Cardiovascular Shielding: Shingles vaccination is associated with a 32% lower risk of heart attack and 25% lower risk of stroke Nguyen et al., 2026.
  • Quasi-Experimental Validation: Studies using birth-date cutoffs (Wales/Canada) provide high-level evidence for a 20% reduction in dementia risk Geldsetzer et al., 2026.
  • Epigenetic Slowdown: Vaccinated individuals exhibit lower biological ages as measured by epigenetic clocks Kim & Crimmins, 2026.
  • Trained Immunity: Live vaccines (e.g., BCG, Oral Polio) reprogram innate immune cells (monocytes/NK cells) to respond more effectively to unrelated pathogens.
  • Neuroinflammatory Burden: Routine vaccinations likely reduce the frequency of systemic inflammatory spikes that accelerate amyloid-beta and tau accumulation.
  • Tdap Synergy: Tetanus, diphtheria, and pertussis (Tdap) vaccination is associated with a 30% reduction in AD risk Harris et al., 2023.
  • Pneumococcal Impact: Pneumonia vaccines show a ~27% reduction in AD risk, potentially by reducing nasopharyngeal colonization of pathogens that trigger neuroinflammation.
  • Healthy User Bias: Observational data may overestimate benefits (e.g., 66% mortality reduction) due to better overall health in vaccinated cohorts.
  • Rapid Mortality Reduction: Cardioprotective effects of the shingles vaccine appear as early as 1–12 months post-injection.
  • Inflammaging Mitigation: Vaccination reduces “background” inflammation, supporting resilience against age-related decline.
  • Cervical Cancer Eradication: High HPV vaccination rates (e.g., Australia) correlate with 50%+ drops in cervical cancer; US regional data shows 3x higher cancer rates in low-vaccine areas.
  • Social Determinants: Trust in science is a significant predictor of health outcomes, often outweighing biological factors in population-level data.
  • The “Natural Experiment” Advantage: Using eligibility cutoffs removes the “choice” element, effectively mimicking a randomized controlled trial (RCT).
  • Off-Target Hierarchy: Live-attenuated vaccines generally show stronger non-specific benefits than inactivated vaccines.

III. Adversarial Claims & Evidence Table

Claim from Video Speaker’s Evidence Scientific Reality (Current Data) Evidence Grade Verdict
High-dose flu vaccine reduces AD by 54% UT Houston study (Schultz) Confirmed. 192k patient cohort showed 55% reduction Schultz et al., 2026. C Strong Support
Shingles vaccine cuts cardiac events by 46% Robert Nguyen (ACC 2026) TriNetX database (246k patients) confirms 46% MACE reduction Nguyen et al., 2026. C Plausible
Shingles vaccine slows aging by 19% Eileen Crimmins (USC) USC study (3.8k adults) showed lower inflammation/biological age Kim & Crimmins, 2026. C Plausible
Vaccines do not cause autism Paul Offit & Data Science Consensus: Multiple meta-analyses (N > 1.2M) show zero link Taylor et al., 2014. A Strong Support
Shingles vaccine reduces dementia by 20% Wales/Canada Cutoff Study Regression Discontinuity study confirms 20% reduction Geldsetzer et al., 2026. B-equivalent Strong Support
Tdap reduces AD risk Schulz/Harris Team Claims-based cohort study showed RR 0.70 (30% reduction) Harris et al., 2023. C Strong Support

IV. Actionable Protocol (Prioritized)

High Confidence Tier (Strong Evidence)

  1. Flu Vaccination (>65): Request the High-Dose (Fluzone High-Dose Quadrivalent) or Adjuvanted (Fluad) formulation. The higher antigen content (60mcg vs 15mcg) correlates with superior neuroprotection.
  2. Shingles Vaccination (>50): Complete the two-dose Shingrix series. The cardioprotective and neuroprotective benefits are consistent across multiple databases and quasi-experimental designs.
  3. Tdap Maintenance: Ensure a booster every 10 years. Recent data suggests pertussis/tetanus immunity is uniquely linked to lower neuroinflammatory markers.

Experimental Tier (Emerging Data)

  1. Pneumococcal Series: Complete the CDC-recommended series (PCV15/20). Observational data suggests a ~27% reduction in AD risk, likely through the prevention of nasopharyngeal-to-brain pathogen translocation.
  2. Biological Age Monitoring: For those interested in longevity, track biological age markers (e.g., GlycanAge, epigenetic clocks) before and after shingles/flu vaccination to measure individual “inflammaging” response.

Red Flag Zone (Safety Data Absent/Unsupported)

  1. Anti-Vaccine Anecdotes: Disregard reports of “vaccine-induced autism” or “sudden death” without peer-reviewed epidemiological verification. The signal for these events in datasets of millions is non-existent.
  2. Healthy User Over-inference: Do not assume a 66% mortality reduction in isolation. Vaccines are an adjunct to, not a replacement for, primary cardiovascular prevention (BP control, lipids, smoking cessation).

V. Technical Mechanism Breakdown

The “Off-Target” effects of vaccines are mediated through several complex biological pathways:

  1. Trained Immunity (Epigenetic Reprogramming): Live vaccines (e.g., BCG, Shingles-Zostavax, Oral Polio) induce epigenetic changes in myeloid cells (monocytes, macrophages) and Natural Killer (NK) cells. This “reprogramming” involves histone modifications (e.g., H3K4me3) and metabolic shifts (increased glycolysis), allowing these cells to mount a more robust, non-specific response to a wide range of subsequent infections.
  2. Mitigation of Inflammaging: Chronic, low-grade inflammation (driven by pathogens like Herpes Zoster or chronic Influenza exposure) accelerates senescent cell accumulation. By preventing these viral reactivations/infections, vaccines reduce the systemic “SASP” (Senescence-Associated Secretory Phenotype) burden, protecting the blood-brain barrier and reducing neuroinflammation.
  3. Cross-Reactivity: Some vaccine-induced antibodies may exhibit molecular mimicry, binding to or interfering with pathogenic proteins involved in chronic diseases (e.g., potentially reducing the seeding of amyloid-beta).
  4. Endothelial Protection: Viral infections (like Flu or Shingles) cause acute endothelial dysfunction and pro-thrombotic states. Vaccination prevents the vascular “insults” that lead to plaque rupture, heart attacks, and strokes.

Additional Data Needed: Large-scale prospective RCTs specifically designed to measure AD/CVD outcomes as primary endpoints are needed to confirm the effect size currently suggested by observational data.

6 Likes
#3

I had known this and shared it in various forums.

Flu vaccine (ref)

  • [RCT] 11%-42% reduction in all cause mortality in RCTs and prospective cohort studies (ref, ref, ref).
  • [Association] 43% reduction in all cause mortality, which was a very consistent finding across 40+ studies (ref, ref).
  • [Association] All cause mortality was reduced in adults with diabetes (ref), hypertension (ref), cardiovascular disease (ref), cancer (ref).
  • [Association] Lowered Alzheimer’s risk by 25-40% (ref, ref).

We also know that chronic viruses tend to age you (EBV, HSV, CMV etc). Many references on that. In one study covid vaccine was associated with epigenetic younging while covid itself was associated with epigenetic aging. Shared and discussed in the Facebook Rapamycin group.

3 Likes
#4

Just had my Shingles shot for that purpose. Skipped all the flu shorts of last 5 years and will resume in the winter time.

I myself is still doing 1mg a day and mainly I have continued flair up of eczema and it beats to be be prednisone.

My blood work though are all good, no immune suppresion seeing nor had any cold sores.

1 Like
#5

Speaking of Rapamycin, I am not clear who are the “cutting edge” people are still on Rapamycin. Peter came off. Peter Diamonds came off. Of course BJ. What did we miss?

#6

You seem to be following it more closely. I took it for ~1.5 yrs (mainly for longevity) and came off, because I started another immunosupressive drug and doubling down isn’t beneficial.

1 Like
#7

I went off because I got painful mouth sores even at a low dose.

1 Like
#8

The High-Dose Defense: Can Enhanced Flu Vaccines Stall Alzheimer’s?

The medical community has long viewed vaccines through a narrow lens: tools to prevent specific infections. However, a massive retrospective cohort study published in Neurology suggests that the immune-boosting effects of the high-dose inactivated influenza vaccine (H-IIV) may offer a “off-target” benefit that is far more profound: a significant reduction in the risk of Alzheimer’s Dementia (AD).

Analyzing data from over 160,000 unique participants aged 65 and older , researchers utilized Target Trial Emulation to compare those receiving the high-dose vaccine against those receiving the standard-dose version. The results indicate that H-IIV was associated with a statistically significant lower risk of incident AD for up to 25 months post-vaccination. While previous research had already established that flu vaccination generally reduces dementia risk by approximately 40% , this study is the first to demonstrate a dose-dependent relationship.

The data also revealed a striking sex-based divergence. The protective association was notably more robust and durable in women, persisting for 13 to 17 months. In contrast, the effects in men were only significant in specific analyses during a later window of 17 to 24 months. This suggests that the female immune system may be more responsive to the immunogenic enhancements of the high-dose vaccine, potentially leading to more effective modulation of the neuroinflammatory pathways that drive Alzheimer’s.

Whether this protection stems from a reduction in severe influenza infections—which are known to trigger systemic and neuro-inflammation —or from “trained immunity” that helps the brain clear toxic pathologies remains a matter of scholarly debate. While the study is limited by its 3-year follow-up and reliance on insurance claims , it provides a compelling case for re-evaluating how we deploy existing immunotherapies to combat age-related cognitive decline.

Actionable Insights

For individuals seeking to optimize their longevity and cognitive health, this study offers several direct, evidence-based takeaways:

  • Opt for High-Dose Over Standard: If you are over 65, the high-dose influenza vaccine (Fluzone High-Dose) appears superior to standard-dose formulations not just for infection prevention, but for potentially reducing Alzheimer’s risk.

  • Annual Consistency is Key: The data suggests the protective effect may depend on repeated vaccination at least every two years. Longevity enthusiasts should prioritize an annual flu shot to maintain these immunomodulatory benefits.

  • Female Biological Advantage: Women appear to derive a more robust neuroprotective benefit from high-dose antigen exposure. This highlights the importance of dose-optimized vaccines for women in late-life neuroprotection strategies.

  • Adjuvanted Alternatives: For those where high-dose vaccines are unavailable, adjuvanted vaccines (A-IIV) also showed a delayed but significant reduction in AD risk in some analyses, though less robust than the high-dose primary findings.

  • Targeting Inflammaging: This study supports the broader biohacking thesis that controlling systemic inflammation via immune-modulatory interventions (like vaccines) can have profound effects on organ-specific aging, particularly the brain.

Source:

  • Open Access Paper: Risk of Alzheimer Dementia After High-Dose vs Standard-Dose Influenza Vaccination
  • Institution: Department of Neurology, The McGovern Medical School at UTHealth, Houston, TX; Massachusetts General Hospital, Boston.
  • Country: United States.
  • Journal Name: Neurology.
    Impact Evaluation The impact score (CiteScore/JIF) of this journal is approximately 10–12, evaluated against a typical high-end range of 0–60+ for top general science journals like Nature or NEJM; therefore, this is a High impact journal within the field of clinical neurology.
4 Likes
#9

I’ve discovered that Wallgreens and maybe also CVS typically refuse people over 45 getting HPV vaccine, which in men is associated with greatly lowered risk of various cancers. They refuse because FDA does not recommend people over age 45 getting it, arguing it is most effective at lower age ranges.

One would need a doctor to prescribe the vaccine.

#10

What state have you seen this in? I wonder if its a state-by-state sort of thing, or a company-wide policy.

#11

I found it following a Google search, and didn’t look specifically at what states allow.it. e.g.

https://www.walgreens.com/topic/pharmacy/scheduler/human-papillomavirus-hpv-vaccine_36.jsp

The HPV vaccine may be given to adults ages 27–45, based on discussions between the patient and their healthcare provider.

When I wrote in the Google search “wallgreens doesnt typically allow people over 50 to get a hpv vaccine” it said

That is correct. Based on Walgreens scheduling policies and CDC guidelines as of 2026, the HPV vaccine is generally only recommended and administered up to age 45.

  • Age 45+ Limit: The vaccine is not approved or recommended for adults older than 45.
  • Why the restriction? The vaccine works best when given before any exposure to HPV. Health experts indicate that by age 45, most adults have already been exposed to HPV, making the vaccine less effective.
  • Walgreens/Pharmacy Practice: Pharmacists typically follow CDC guidelines and clinical decision-making, which do not routinely recommend the vaccine for adults over 26, and specifically stop at 45.
  • Alternatives: Individuals over 45 should consult their doctor to discuss their specific health risks and potential benefits, although they may not be able to receive the vaccine at a retail pharmacy.

For individuals in the 27-45 age range, the CDC recommends shared clinical decision-making with a doctor.

1 Like